slides · global inventory
Solution
Slide type collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 8,880
Current window 4,591-4,620
Pages 296
Rows per page 30
Slide type
4,591-4,620 of 8,880
13
The slide uses a comparative framework to justify the need for the company's battery-buffered technology.ads-tec Energy | SPAC Presentation Deck | 43 slides · ads-tec Energy
Pitch deck Investment bank Beat · Solution1 hit
14
The slide uses a comparative layout to showcase product portfolio capabilities.ads-tec Energy | SPAC Presentation Deck | 43 slides · ads-tec Energy
Pitch deck Investment bank Beat · Solution1 hit
13
The slide uses a split-screen layout to contrast the disease state (pathophysiology) with the therapeutic intervention (product concept).Tenaya Therapeutics | IPO Presentation Deck | 36 slides · Tenaya Therapeutics
Pitch deck Investment bank Beat · Product1 hit
16
The slide uses a three-column layout to present histological, VCN (vector copy number), and protein expression data.Tenaya Therapeutics | IPO Presentation Deck | 36 slides · Tenaya Therapeutics
Pitch deck Investment bank Beat · Product1 hit
17
The slide uses two distinct charts to show tissue specificity (bar chart) and functional efficacy (line chart with error bars).Tenaya Therapeutics | IPO Presentation Deck | 36 slides · Tenaya Therapeutics
Pitch deck Investment bank Beat · Product1 hit
21
Includes anatomical pathology image and molecular structure diagram of desmosomes.Tenaya Therapeutics | IPO Presentation Deck | 36 slides · Tenaya Therapeutics
Pitch deck Investment bank 1 hit
24
The slide uses a combination of a bar chart for transduction ratios and a scatter plot for ventricular specificity to validate the efficacy of the TNC-CM series capsids.Tenaya Therapeutics | IPO Presentation Deck | 36 slides · Tenaya Therapeutics
Pitch deck Investment bank 1 hit
26
Includes a biological mechanism diagram showing how HDAC6 inhibitors target multiple pathways leading to diastolic dysfunction and HFpEF.Tenaya Therapeutics | IPO Presentation Deck | 36 slides · Tenaya Therapeutics
Pitch deck Investment bank 1 hit
27
The slide outlines a proprietary R&D pipeline for identifying and validating drug targets using patient-derived cells and machine learning.Tenaya Therapeutics | IPO Presentation Deck | 36 slides · Tenaya Therapeutics
Pitch deck Investment bank 1 hit
31
The slide uses a bar chart to show selectivity and a dose-response curve to show safety (thrombocytopenia risk).Tenaya Therapeutics | IPO Presentation Deck | 36 slides · Tenaya Therapeutics
Pitch deck Investment bank 1 hit
34
Includes a biological mechanism diagram and a line chart showing Ejection Fraction improvement in murine models.Tenaya Therapeutics | IPO Presentation Deck | 36 slides · Tenaya Therapeutics
Pitch deck Investment bank 1 hit
35
The slide uses a three-column layout: Disease Overview, Product Concept, and In Vivo Data.Tenaya Therapeutics | IPO Presentation Deck | 36 slides · Tenaya Therapeutics
Pitch deck Investment bank 1 hit
06
The slide uses a process flow to explain the 'Learning' phase of their technology platform.TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank Beat · SolutionLoop · Golden Circle1 hit
07
The slide title is likely a continuation from a previous slide (e.g., '...to treat patients who are not eligible for standard therapies').TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank Beat · SolutionLoop · Golden Circle1 hit
08
Uses a before-after-bridge style logic to illustrate the clinical advantage of multiplexing.TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank Beat · SolutionLoop · Golden Circle1 hit
12
Uses a before-after-bridge framework to contrast current therapy limitations with TScan's solution.TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank Beat · SolutionLoop · Golden Circle1 hit
13
The slide uses a process flow diagram to explain a proprietary biotechnology platform.TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank Beat · SolutionLoop · Golden Circle1 hit
14
The slide uses a Venn diagram to explain the scope of their target discovery platform.TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank Beat · SolutionLoop · Golden Circle1 hit
17
The slide illustrates a dual-platform approach to TCR discovery and validation.TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank Beat · SolutionLoop · Golden Circle1 hit
18
The slide uses a flow-chart style diagram to position TScan's technology as an evolution of current standard-of-care cell therapies.TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank Beat · SolutionLoop · Golden Circle1 hit
23
The slide uses a circular process flow to show the interaction between the patient's condition and the donor-derived TCR therapy.TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank 1 hit
24
The slide shows three distinct charts: a time-course line graph, a bar chart for survival at 90 hours, and a bar chart comparing cell viability across different HA-1 genotypes in AML and ALL cell lines.TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank Beat · Traction1 hit
26
The chart shows a scatter plot where the vast majority of data points are at zero, indicating no off-target binding.TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank Beat · Traction1 hit
27
The slide uses a process flow to explain patient stratification for a clinical trial.TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank Beat · Traction1 hit
29
Uses a Venn diagram to show overlap in Head & Neck cancers, and a central 'ImmunoBank' repository feeding into multiplexed TCR-T arms.TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank Beat · Traction1 hit
32
The chart shows fold-enrichment of protein fragments, highlighting three specific targets identified from patient data.TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank Beat · Traction1 hit
33
The chart uses a log scale on the y-axis to compare expression levels across multiple tissue types.TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank Beat · Traction1 hit
36
The slide uses a process flow to explain the mechanism of action for the company's platform.TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank 1 hit
38
The slide uses a diagram to illustrate the mechanism of the T-Integrate system (transposon/transposase integration into T cell DNA).TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank 1 hit
10
The slide uses a 5-column layout to highlight key product attributes.Zevia | IPO Presentation Deck | 46 slides · Zevia
Pitch deck Investment bank Beat · SolutionLoop · Cost Of Inaction1 hit